TEAR SUBSTITUTES PREVENT OPHTHALMIC COMPLICATIONS IN INTENSIVE CARE UNIT PATIENTS
https://doi.org/10.18008/1816-5095-2015-2-48-53
Abstract
Aim. To study the effects of Cationorm for the prevention of ophthalmic complications in intensive care unit (ICU) patients and to compare the efficacy of ocular surface lubricants used in ICU. Patients and methods. 50 ICU patients (100 eyes) with bilateral lagophthalmos (2 mm or more) were enrolled in the study. Study group and control group each included 25 patients (50 eyes) who were on deep sedation and ventilator. Before and after the treatment, general examination, biomicroscopy, tonometry, ophthalmoscopy, Schirmer’s test and Norn’s test (with fluorescein) were performed. Results. Cationorm significantly improves tear film stability without any corneal epithelial defects (100 % of patients). In 7 controls (14 eyes, 28 %), initial signs of corneal xerosis and exposure keratitis were revealed. Conclusions. ICU patients are at high risk of complications due to hypodynamia and reduced innervation of the eye and its appendages. Bilateral lagophthalmos develops in 16.67 % of ICU patients who are on deep sedation and ventilator (up to 3 days). In the abscence of preventive therapy, lagophthalmos results in complications, i.e., keratitis and, occasionally, corneal ulceration and perforation. ICU patients require ophthalmological examination and tear substitutes. Regular instillations of Cationorm minimize ophthalmic complications due to intensive therapy. Cationorm restores tear firm architectonics and may be considered as a first-line choice for such disorders.
About the Authors
S. A. Kochergin
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
Russian Federation
Department of Ophthalmology
Contact information : Kochergin Aleksandr Sergeevich, pure_eye@mail.ru
A. S. Kochergin
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
Department of Ophthalmology
Russian Federation
Department of Ophthalmology
O. P. Koshevaya
Clinical City Hospital No67, Moscow
Russian Federation
Russian Federation
References
1. Herbert L. Ophthalmology in anesthesia and intensive care. Anaesth Intensive Care Med. 2004; 5 (9): 304‑307.
2. Brzheskiy V. V., Astakhov Yu. S., Kuznetsova N. Yu. [Lacrimal apparatus disorders: Guidelines for practitioners]. Zabolevaniya sleznogo apparata: posobie dlya praktikuyushchikh vrachey. St. Petersburg, N-L, 2009. (in Russ.).
3. Mackie I. A. Neuroparalytic keratitis. In: Fraunfelder F., Roy F. H., Meyer S. M., eds. Current Ocular Therapy. Philadelphia, WB Saunders; 1995: 452-454.
4. Doane M. G. Interaction if eyelids and tears in corneal wetting and the dynamics of the normal human eyeblink. Am. J. Ophthalmol. 1980; 89 (4): 507-516.
5. Behrens A., Doyle J. J., Stern L., Chuck R. S., McDonnell P. J., Azar D. T., Dua H. S., Hom M., Karpecki P. M., Laibson P. R., Lemp M. A., Meisler D. M., Del Castillo J. M., O’Brien T. P., Pflugfelder S. C., Rolando M., Schein O. D., Seitz B., Tseng S. C., van Setten G., Wilson S. E., Yiu S. C.; Dysfunctional tear syndrome study group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006; 25 (8): 900-907.
6. Lallemand F., Daull P., Benita S., Buggage R., Garrigue J. S. Successfully improving ocular drug delivery using the cationic nanoemulsion, Novasorb. J. Drug. Deliv. 2012; 2012:604204.
7. Liang H., Brignole-Baudouin F., Rabinovich-Guilatt L., Mao Z., Riancho L., Faure M. O., Warnet J. M., Lambert G., Baudouin C. Reduction of quaternary ammonium-induced ocular surface toxicity by emulsions: an in vivo study in rabbits. Mol. Vis. 2008; 14: 204-216.
8. Ousler G. W. 3rd, Hagberg K. W., Schindelar M., Welch D., Abelson M. B. The Ocular Protection Index. Cornea. 2008; 27 (5): 509‑513.
9. Du Toit L. C., Pillay V., Choonara Y. E., Govender T., Carmichael T. Ocular drug delivery — A look towards nanobioadhesives. Expert Opin. Drug Deliv. 2011; 8 (1): 71‑94.
10. Aragona P., Spinella R., Rania L., Postorino E., Roszkowska A., Versura P. Assessment of the efficacy of CATIONORM in patients with moderate dry eye compared with Optive® and Emustil®. Acta Ophthalmol. 2011; 89: s246.
11. Groos Jr. E. B. Neurotrophic keratitis. In: Krachmer J. H., Mannis M. J., Holland E. J., eds. Cornea: Clinical Diagnosis and Management. St Louis, Mosby; 1997: 1340.
12. Daull P., Lallemand F., Garrigue J. S. Benefits of cetalkonium chloride cationic oilin-water nanoemulsions for topical ophthalmic drug delivery. J. Pharm. Pharmacol. 2014; 66 (4): 531-541.
Review
For citations:
Kochergin S.A., Kochergin A.S., Koshevaya O.P. TEAR SUBSTITUTES PREVENT OPHTHALMIC COMPLICATIONS IN INTENSIVE CARE UNIT PATIENTS. Ophthalmology in Russia. 2015;12(2):48-53. (In Russ.) https://doi.org/10.18008/1816-5095-2015-2-48-53
Views:
1744
Email this article 